SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Michelle Zaepfel, Lisa Cristofaro, Allison Trawinski, Katharine McCarthy, Elizabeth Rightmier, Tina Khadem, Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy, Annals of Pharmacotherapy, 2017, 51, 4, 307

    CrossRef

  2. 2
    William D. Trombatt, Pamela H. Koerner, Zoie N. Craft, Richard T. Miller, Khalid M. Kamal, Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection, Journal of Pharmacy Practice, 2017, 30, 2, 154

    CrossRef

  3. 3
    Sauzanne Khalilieh, Hwa-Ping Feng, Ellen G. J. Hulskotte, Larissa A. Wenning, Joan R. Butterton, Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions, Clinical Pharmacokinetics, 2015, 54, 6, 599

    CrossRef

  4. 4
    Priya Simoes, Adel Asaad, Jean Abed, Ellen S. Engelson, Donald P. Kotler, Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population, Women's Health Issues, 2015, 25, 3, 289

    CrossRef

  5. 5
    Leora Schiff, Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi, Clinical Therapeutics, 2015, 37, 5, 1092

    CrossRef

  6. 6
    Louis S. Matza, Sandhya J. Sapra, John F. Dillon, Anupama Kalsekar, Evan W. Davies, Mary K. Devine, Jessica B. Jordan, Amanda S. Landrian, David H. Feeny, Health state utilities associated with attributes of treatments for hepatitis C, The European Journal of Health Economics, 2015, 16, 9, 1005

    CrossRef

  7. 7
    Chi-Chieh Yang, Wei-Lun Tsai, Wei-Wen Su, Chung-Feng Huang, Pin-Nan Cheng, Ching-Chu Lo, Kuo-Chih Tseng, Lein-Ray Mo, Chun-Hsiang Wang, Shih-Jer Hsu, Hsueh-Chou Lai, Chien-Wei Su, Chun-Jen Liu, Cheng-Yuan Peng, Ming-Lung Yu, Chen-Hua Liu, Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients, PLOS ONE, 2015, 10, 9, e0137852

    CrossRef

  8. 8
    Ruian Ke, Claude Loverdo, Hangfei Qi, Ren Sun, James O. Lloyd-Smith, Roger Dimitri Kouyos, Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection, PLOS Computational Biology, 2015, 11, 6, e1004040

    CrossRef

  9. You have free access to this content9
    R. K. Sterling, A. Kuo, V. K. Rustgi, M. S. Sulkowski, T. G. Stewart, J. M. Fenkel, H. El-Genaidi, M. A. Mah'moud, G. M. Abraham, P. W. Stewart, L. Akushevich, D. R. Nelson, M. W. Fried, A. M. Di Bisceglie, Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir, Alimentary Pharmacology & Therapeutics, 2015, 41, 7
  10. 10
    Manuela Rasi, Patrizia Künzler-Heule, Patrick Schmid, David Semela, Philip Bruggmann, Jan Fehr, Susi Saxer, Dunja Nicca, “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis, BMC Infectious Diseases, 2014, 14, 1

    CrossRef

  11. You have free access to this content11
    L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung, L. A. Mole, Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort, Alimentary Pharmacology & Therapeutics, 2014, 39, 1
  12. You have free access to this content12
    Marc Bourlière, Xavier Adhoute, Astrid Wendt, Christelle Ansaldi, Valérie Oules, Paul Castellani, How to optimize current therapy of HCV genotype 1 infection with boceprevir, Liver International, 2014, 34,
  13. 13
    Louise Berry, Will Irving, Predictors of hepatitis C treatment response: what's new?, Expert Review of Anti-infective Therapy, 2014, 12, 2, 183

    CrossRef

  14. 14
    Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Katsuhiko Iwakiri, Chiaki Kawamoto, Yoshio Aizawa, Choitsu Sakamoto, Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C, Digestive and Liver Disease, 2014, 46, 8, 738

    CrossRef

  15. You have free access to this content15
    E. Ogawa, N. Furusyo, M. Nakamuta, E. Kajiwara, H. Nomura, K. Dohmen, K. Takahashi, T. Satoh, K. Azuma, A. Kawano, Y. Tanabe, K. Kotoh, S. Shimoda, J. Hayashi, Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study, Alimentary Pharmacology & Therapeutics, 2013, 38, 9